Providers

In a phase 3 trial, the investigational oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by nearly 60% in adults with or at risk for ASCVD.

Experts at AHA 2025 outlined how digital tools, inclusive trials, and safer deprescribing can reshape cardiovascular care for aging adults.

Gefurulimab shows significant improvements in myasthenia gravis (MG) symptoms, offering a convenient self-administered treatment option for patients.

Ritlecitinib significantly improves hair regrowth and reduces psychosocial burdens in patients with alopecia areata, enhancing emotional well-being over time.

Key factors influencing chronic urticaria duration highlight the importance of early identification and management in primary care settings.

Research shows how low-dose aspirin, lifestyle habits, and the Life’s Essential 8 checklist can affect cardiovascular risk in patients with type 2 diabetes.

In the phase 3 BRAVE-AA-PEDS trial, baricitinib led to significant scalp, eyelash, and eyebrow hair regrowth at 1 year in adolescents with alopecia areata.

Lisa Taylor-Swanson, PhD, explains how including Indigenous and Hispanic women in conversations around menopause care helps fine-tune interventions.

The case shows how such cardiac involvement can mimic neurologic disease and demand complex, multidisciplinary management.

Despite social media frenzy, there is limited evidence around testosterone’s impact on muscle, mood, and other menopausal symptoms.

Bariatric surgery halves mortality and reduces liver, heart, and kidney complications in steatotic liver disease vs nonsurgical care.

The study underscores the importance of repeat testing in cases where myelin oligodendrocyte glycoprotein immunoglobulin G tests are borderline.

Despite improved selectivity, real-world data point to persistent cardiovascular challenges even with next-generation BTKi therapies.

A recent study reveals a heightened stroke risk in asthma patients recovering from severe COVID-19, emphasizing the need for proactive monitoring and management.

There is a significant link between chronic spontaneous urticaria and cardiovascular disease risk, highlighting the need for routine assessments.

Hair loss disorder can lead to a significant psychological and emotional burden that warrants more attention, new research suggests.

Deuruxolitinib 8 mg BID was found to be the most effective oral JAK inhibitor for severe alopecia areata in a new meta-analysis.

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Combining ELR with CT-based measures predicts olfactory recovery in CRSwNP patients, highlighting eosinophils' role in disease severity and dysfunction.

Experts at AMCP Nexus 2025 highlighted how real-world data can improve CAR T-cell therapy access and outcomes.

Metabolic intermediates were identified as active participants in fibrosis progression and potential targets for next-generation therapies.

Real-world data suggest metabolic dysfunction-associated steatotic liver disease is also associated with higher all-cause mortality.

Previous research has evaluated PD-1/PD-L1 immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC), but research in the setting of limited-stage disease is sparse.

Radiomic assessment has been used to distinguish multiple sclerosis from similar disorders, and it might also be useful in identifying MS stages and subtypes.

Overlapping metabolic mechanisms drive both chronic kidney disease (CKD) and valvular heart disease (VHD), a new review outlined.